WuXi Biologics plans on-market share buyback of up to US$400 million

• WuXi Biologics launched an on-market share repurchase program with an aggregate cap of USD 400 million.
• Board resolution dated May 24, 2026; buybacks to be executed from time to time in the open market.
• Program to use an existing repurchase mandate that allows up to 406,868,077 shares, equal to 10% of shares outstanding at June 6, 2025.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Wuxi Biologics (Cayman) Inc. published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260526-12170044), on May 26, 2026, and is solely responsible for the information contained therein.